Pricing Log in Create free account

Karyopharm Therapeutics Inc. (KPTI) vs XTL Biopharmaceuticals Ltd. (XTLB)

Karyopharm Therapeutics Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. Karyopharm Therapeutics Inc. and XTL Biopharmaceuticals Ltd. are of similar size ($8.1M and $8.0M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −12.7%. XTL Biopharmaceuticals Ltd. has the higher net margin (0.00% vs −153.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, XTL Biopharmaceuticals Ltd. leads on 8 and Karyopharm Therapeutics Inc. on 7.

Valuation

Metric KPTI XTLB Biotechnology median
P/E n/m n/m 8.50
P/S 0.08 1.36 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.34 1.27 9.21
Earnings yield (3,634.56%) (14.29%) (33.15%)
Free cash flow yield (580.28%) (139.25%) (25.50%)

Profitability

Metric KPTI XTLB Biotechnology median
Gross margin 95.89% 0.00% 65.16%
Operating margin (56.17%) 0.00% 0.00%
Net margin (153.28%) 0.00% 0.00%
Free cash flow margin (44.57%) 0.00% 0.00%
Return on equity 78.98% 0.00% (56.36%)
Return on assets (207.90%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KPTI XTLB Biotechnology median
Revenue growth (TTM) 6.81% (12.71%) 6.02%
EPS growth (last fiscal year) (98.37%) (159.17%) 30.26%
Revenue growth, 5-year CAGR 6.21% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KPTI XTLB Biotechnology median
Debt to equity (0.76) (1.83) 0.00
Current ratio 0.79 0.70 4.72
Net debt to EBITDA (2.03) (0.11) 0.96

Dividend

Metric KPTI XTLB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KPTI XTLB Biotechnology median
Market cap 7.95m 8.10m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack